由国家遗传工程小鼠资源库合作共建单位江苏集萃药康生物科技有限公司利用基因编辑技术，自主研发，供应，保存。应用领域为：1) 筛选人源 PDL1 抑制剂或人源 PD1 抑制剂； 2) 人源 PDL1 抑制剂及人源 PD1 抑制剂联合用药药效及安全性评价； 3) 抗肿瘤研究； 4) 自身免疫病研究 1) 筛选人源 PDL1 抑制剂或人源 PD1 抑制剂； 2) 人源 PDL1 抑制剂及人源 PD1

中国科技资源共享网2024-01-19 更新100

Table_3_Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy.DOCX

免疫治疗生物标志物

PD-1/PD-L1抑制剂疗效

Identification of reliable biomarkers to predict efficacy of immune checkpoint inhibitors and to monitor relapse in cancer patients receiving this therapy remains one of the main objectives of cancer

NIAID Data Ecosystem40

DataSheet_1_Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1.zip

非小细胞肺癌免疫治疗

PD-1/PD-L1抑制剂疗效

ObjectivesImmune checkpoint inhibitors (ICIs) of programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) have been rapidly adopted in US clinical practice for first-line therapy of metasta

NIAID Data Ecosystem20

Study for biomarkers in predicting the efficacy of PD-1 monoclonal antibody in gastrointestinal cancer

PD-1/PD-L1抑制剂疗效

生物标志物建模

Interventions: Gold Standard:Clinical outcome;Index test:multi-parameter combination model Primary outcome(s): SEN, SPE, ACC, AUC of ROC Study Design: Sequential

NIAID Data Ecosystem50

Long-term resident adipose-derived stromal stem cells in the microenvironment remodeling BLCA cell stemness and EMT promotes bladder cancer progression

肿瘤微环境

膀胱癌进展机制

The role of adipose-derived stromal stem cells (ADSCs) in BLCA progression is unclear. We investigated the effects of invasion, stemness, Epithelial-mesenchymal transition (EMT), and drug resistance o

NIAID Data Ecosystem30